PMID- 37250880
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240502
IS  - 0973-6883 (Print)
IS  - 2213-3453 (Electronic)
IS  - 0973-6883 (Linking)
VI  - 13
IP  - 3
DP  - 2023 May-Jun
TI  - Association of HLA DRB1 Allele Profile with Pediatric Autoimmune Liver Disease in 
      India.
PG  - 397-403
LID - 10.1016/j.jceh.2023.01.001 [doi]
AB  - OBJECTIVES: The aim of this study is to study the association of human leukocyte 
      antigen (HLA) DRB1 alleles with treatment response in Indian children with 
      autoimmune liver disease (AILD). METHODS: HLA DRB1 alleles of 71 Indian children 
      with pediatric AILD (pAILD) were analyzed along with 25 genetically confirmed 
      patients with Wilson disease as controls. After 1 year of therapy, all those who 
      failed to normalize aspartate & alanine transferase (AST/ ALT) (below 1.5 times 
      of upper limit of normal) and/or failed to normalize IgG levels, or who had >2 
      relapses (AST/ALT levels >1.5 times of upper limit of normal) while on treatment, 
      were labeled as difficult to treat (DTT). RESULTS: HLA DRB1 *3 was found to be 
      significantly associated with AIH type 1 (46.2% vs. 4% in controls; P 
      corrected = 0.011). Majority of the patients [55 (77.5%)] had chronic liver 
      disease at presentation, with 42 (59.2%) having portal hypertension and 17 
      (23.9%) having ascites. Out of the 71 with pAILD, 19 (26.8%) were DTT. HLA 
      DRB1 *14 was found to be independently associated with DTT cases (36.8% vs. 9.6%, 
      OR 5.87, 95% CI 1.07-32.09, P = 0.041). Other factors independently associated 
      with DTT were presence of autoimmune sclerosing cholangitis (OR 8.57, P = 0.008) 
      and high-risk varices (OR 7.55, P = 0.016), improving the correctness of 
      classification of the model from 73.2% to 84.5%. CONCLUSION: HLA DRB1 *14 is 
      independently associated with treatment response in pAILD and HLA DRB1 *3 is 
      associated with AIH type 1. HLA DRB1 alleles may thus provide supportive 
      information for diagnosis and prognosis of AILD.
CI  - (c) 2023 Indian National Association for Study of the Liver. Published by Elsevier 
      B.V. All rights reserved.
FAU - Maria, Arjun
AU  - Maria A
AD  - Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New 
      Delhi, India.
FAU - Sood, Vikrant
AU  - Sood V
AD  - Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New 
      Delhi, India.
FAU - Khanna, Rajeev
AU  - Khanna R
AD  - Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New 
      Delhi, India.
FAU - Lal, Bikrant B
AU  - Lal BB
AD  - Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New 
      Delhi, India.
FAU - Trehanpati, Nirupama
AU  - Trehanpati N
AD  - Department of Molecular and Cellular Medicine, Institute of Liver and Biliary 
      Sciences, New Delhi, India.
FAU - Alam, Seema
AU  - Alam S
AD  - Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New 
      Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20230105
PL  - India
TA  - J Clin Exp Hepatol
JT  - Journal of clinical and experimental hepatology
JID - 101574137
PMC - PMC10213850
OTO - NOTNLM
OT  - HLA DRB1 allele
OT  - human leukocyte antigen
OT  - pediatric autoimmune liver disease
EDAT- 2023/05/30 13:07
MHDA- 2023/05/30 13:08
PMCR- 2024/05/01
CRDT- 2023/05/30 11:29
PHST- 2022/09/17 00:00 [received]
PHST- 2023/01/02 00:00 [accepted]
PHST- 2023/05/30 13:08 [medline]
PHST- 2023/05/30 13:07 [pubmed]
PHST- 2023/05/30 11:29 [entrez]
PHST- 2024/05/01 00:00 [pmc-release]
AID - S0973-6883(23)00001-4 [pii]
AID - 10.1016/j.jceh.2023.01.001 [doi]
PST - ppublish
SO  - J Clin Exp Hepatol. 2023 May-Jun;13(3):397-403. doi: 10.1016/j.jceh.2023.01.001. 
      Epub 2023 Jan 5.